Hybio Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shenzhen Hanyu Pharmaceutical Co., Ltd. was established in April 2003 and is a national high-tech enterprise specializing in the research, production, and sales of peptide drugs. The company was listed on the Shenzhen Stock Exchange in 2011 (securities code: 300199) and is one of the earliest peptide drug companies listed in China. Hanyu Pharmaceutical has branches including Pingshan Branch, Wuhan Branch, Hong Kong Branch, Gansu Chengji Branch, Dali Branch, etc. Its business covers the fields of pharmaceuticals and medical devices. Its main products include peptide raw materials, customized peptides, beauty peptides, peptide preparations, solid preparations, medical devices, and peptide skincare products. The company has built a national and local joint engineering laboratory for polypeptide drugs, a national public experimental center for polypeptide innovative drugs, and a national pilot test technology platform for polypeptide drug preparation. It has undertaken a number of national subjects and won the second prize of the the State Technological Innovation Award, the Chinese Patent Excellence Award, the National Intellectual Property Demonstration Enterprise, the Guangdong Science and Technology Award, the Shenzhen Mayor Award and other national, provincial and municipal honorary awards. The company has 24 peptide drugs, 9 new drug certificates, 26 clinical approvals, and multiple raw materials and formulations have passed GMP certification inspections in the United States, the European Union, South Korea, Brazil, and other countries. They have been sold to overseas markets and have received widespread praise from international customers. The company adheres to the industrial chain layout around the three strategic pillars of "talent, combination of imitation and innovation, and market", actively deepens the strategic layout of the four major treatment fields of gynecology, obstetrics, reproduction, digestion and hemostasis, diabetes, and anti infection based on polypeptide drugs, and creates a market competitive "generic drugs"+"innovative drugs" product pipeline, pilot beauty peptides and other emerging industries with a dual wheel drive model of "self research+integration of domestic and foreign resources", Explore various application scenarios in the field of peptides, achieve diversified operations under the product leadership strategy, and promote the company's sustained, stable, rapid, healthy, and efficient development. As a leading pharmaceutical enterprise in the polypeptide industry, the company fully exploits its own advantages, gradually develops cooperation with high-quality pharmaceutical enterprises and scientific research institutions with complementary resources at home and abroad, actively cooperates with scientific research institutions such as Institute of Microbiology, Chinese Academy of Sciences, Shenzhen Third People's Hospital, Shenzhen National Clinical Medical Research Center for infectious diseases, Shenzhen Advanced Institute of Chinese Academy of Sciences, Shenzhen Bay Laboratory, and cooperates with China Resources Biology, Huiling Pharmaceutical, Minimally Invasive Medicine, China Resources Shuanghe Chinese medicine and other domestic and foreign pharmaceutical enterprises actively practice the strategy of combining imitation with innovation, carry out the layout of innovative drugs, and rapidly promote the research and development, clinical research and application, and industrialization of achievements of innovative drug projects such as anti COVID-19 polypeptide nasal spray drugs, household rapid COVID-19 antigen detection kits. |
| Headquarter | Shenzhen |
| Establish Date | 4/2/2003 |
| Listed Code | 300199.SZ |
| Listed Date | 4/7/2011 |
| Chairman | Zeng Shaogui. |
| CEO | |
| Website | www.hybio.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
